The resignation of directors in the pharmaceutical industry, Zhendong Pharmaceutical also joins the ranks

Zhendong Pharmaceutical issued an announcement on the evening of November 19, stating that the company’s board of directors recently received a written application for resignation from director and president Ma Shifeng.
Mr.
Ma Shifeng, due to personal reasons, applied to resign as a director, president, member of the Board’s Compensation and Appraisal Committee, and member of the Audit Committee of the Board of Directors.
Job title
.
After resigning the above-mentioned position, Ma Shifeng no longer holds any position in the company
.
As of the disclosure date of this announcement, Mr.
Ma Shifeng holds 403,200 shares of the company, and his spouse or other related persons do not hold the company's shares
.
Zhendong Pharmaceutical's main business is relatively diversified, including the research and development, production and sales of vitamins, mineral preparations, traditional Chinese medicines, innovative drugs and other products
.
In October of this year, Zhendong Pharmaceutical sold a 100% stake in Langdi Pharmaceutical, a subsidiary that once contributed 27% of the company's revenue, for 5.
8 billion yuan
.
The company explained that it was mainly due to the greater competitive pressure faced by Langdi Pharmaceuticals
.
According to data, Langdi's pharmaceutical business includes the research and development, production and sales of calcium preparations, vitamins, mineral preparations and other products
.
In 2019, the terminal sales of calcium preparations in China was about 17 billion yuan, with a compound growth rate of only 4.
7%.
In 2020, affected by the epidemic, the size of China's calcium preparations retail market dropped by about 10%
.
The market is becoming saturated, and the future development of Langdi Pharmaceuticals is limited
.
While selling the subsidiary, the controlling shareholder of Zhendong Pharmaceutical also reduced the shares of the listed company
.
On November 16, 2021, the company received its controlling shareholder Zhendong Group’s "Notice on the Early Termination of the Share Reduction Plan".
The reduction plan has been implemented.
A total of 17.
023 million shares of the company were reduced, representing a reduction ratio of 1.
6567%.

.
After this reduction, Shanxi Zhendong Health Industry Group Co.
, Ltd.
holds approximately 374 million shares, accounting for 36.
36% of the total share capital
.
From the sale of subsidiaries and shareholder reductions to the resignation of the company’s directors, it can be seen that the company is facing major challenges
.
Financial data shows that from 2017 to 2020, the company's net profit after non-deduction is 270 million yuan, -179 million yuan, 127 million yuan and 181 million yuan respectively; the growth rate of net profit after non-non-deduction in the same period is 50.
77%,- 166.
28%, 170.
94% and 42.
39%
.
It is worth mentioning that the pharmaceutical industry has recently started to resign from directors
.
In addition to Zhendong Pharmaceutical, there are also a wave of resignations of directors of many pharmaceutical companies
.
For example, Lexin Medical announced on November 11 that many senior executives of the company resigned.
Among them, Ms.
Li Yanbing applied to resign as a director of the third board of directors due to personal reasons, and at the same time resigned as a member of the strategy committee of the third board of directors; after resignation, Li Yanbing Ms.
still serves as the company's senior medical consultant
.
In addition, Mr.
Wang Qingyu will also serve as a member of the strategy committee of the company's third board of directors after being appointed as a director of the company with the approval of the company's general meeting of shareholders
.
On November 12, Hengrui Medicine issued an announcement that Mr.
Yao Jianlin had applied to resign from the company's vice chairman and director due to his reaching retirement age, and at the same time resigned as a member of the company's board of directors, corporate development and strategic investment committee
.
On November 13, First Pharmaceutical issued an announcement stating that Ms.
Xu Ziying had applied for the resignation of the company's 9th Board of Directors, Director, Chairman of the Strategy Committee and member of the Remuneration and Appraisal Committee due to work reasons
.
After resignation, he no longer holds any position in the company
.
On November 18, Cai Aiguo, director of Yingtai Biotechnology, resigned from the board of directors of the company due to physical reasons, and continued to serve as director of the company's subsidiary after resignation
.
At the same time, the board of directors held on November 16 approved and nominated Zhou Shuguang as a director of the company
.
Directors are the core of an enterprise and are mainly responsible for the company's daily operation and management
.
In the context of accelerated adjustment and upgrading of pharmaceutical companies, frequent personnel changes are inevitable
.